Literature DB >> 925478

Characterization of pyruvate kinase from the liver of a patient with aberrant erythrocyte pyruvate kinase, PK Nagasaki.

K Nakashima, S Miwa, H Fujii, K Shinohara, K Yamauchi, Y Tsuji, M Yanai.   

Abstract

The characterization of the L-type PK were made of PK extracted from the liver of a patient with congenital hemolytic anemia associated with an erythrocyte PK variant, PK Nagasaki. The L-type PK of PK Nagasaki showed the following parameters: slow migration on electrophoresis, high Km for PEP without F-1,6-P2, less activation by F-1,6-P2, normal Km for ADP, high utilization of UDP, acidic pH optimum, and instability to urea and heat. These tests served to differentiate this L-type PK variant from the other variants previously reported. At the same time, both the Km for PEP with F-1,6-P2 saturation and the electrophoretic mobility of L-type PK were found to be different from those of the erythrocyte PK and PK Nagasaki. Though the liver cell, with regard to L-type PK, has only the less functional and less stable mutant L-type PK there is no evidence of liver dysfunction or damage, although there is chronic hemolytic anemia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 925478

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  4 in total

Review 1.  Advances in hereditary red cell enzyme anomalies.

Authors:  A Kahn; J C Kaplan; J C Dreyfus
Journal:  Hum Genet       Date:  1979       Impact factor: 4.132

2.  A red cell pyruvate kinase mutant with normal L-type PK in the liver.

Authors:  J Etiemble; C Picat; P Boivin
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

3.  Pyruvate kinase deficiency: novel mutations and a better understanding of the genotype-to-phenotype correlation in Brazilian patients.

Authors:  Rodolfo Delfini Cançado
Journal:  Rev Bras Hematol Hemoter       Date:  2017-12-06

Review 4.  Regulation of pyruvate metabolism and human disease.

Authors:  Lawrence R Gray; Sean C Tompkins; Eric B Taylor
Journal:  Cell Mol Life Sci       Date:  2013-12-21       Impact factor: 9.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.